Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Novimmune

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

- PMLiVE

ACPs to lead gene therapies in haemophilia market growth

New therapies to hit existing players

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

BioMarin prepares for haemophilia A gene therapy data readout, filing

Key long-term data expected in July

- PMLiVE

Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion

- PMLiVE

Takeda secures investor backing for £46bn Shire takeover

The deal is expected to close early next year

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

- PMLiVE

Shire’s angioedema drug Takhzyro recommended in Europe

Analysts expect the drug to make around $1.8bn in peak sales

Bayer symbol

Bayer roll-out of haemophilia drug Jivi gathers pace

Japan’s MHLW is next to approve the drug

- PMLiVE

Shire’s bleeding disorder drug approved in Europe

Veyvondi for patients with rare disease von Willebrand disease

- PMLiVE

Takeda rebels take aim at Shire acquisition

Shareholder group concerned about $30bn debt burden

- PMLiVE

Shire claims US okay for HAE blockbuster-in-waiting

FDA approves Takhzyro as a preventative measure for HAE attacks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links